Listen to the audio version of this article (generated by AI).
Listen to the audio version of this article (generated by AI).
From the rise of outcome-based payment models to the intensifying pace of mergers and acquisitions (M&A), and the ripple effects of EU-U.S. trade tensions, these trends present both challenges and opportunities for Hungarian stakeholders. Ildikó Ádám, PhD – EY, partner, Life Sciences Industry leader – Europe Central region, shares her insights on how these trends are reshaping Hungary’s pharmaceutical landscape.
Globally, healthcare systems are shifting toward outcome-based payment models, which link reimbursement to the actual health benefits delivered to patients. These models promise better value for money and more sustainable healthcare spending. However, their implementation in the Central and Eastern European (CEE) region, including Hungary remains challenging.
Hungary’s centralized healthcare system and health technology assessment (HTA) processes offer a theoretical foundation for such models, but practical barriers persist. The country lacks a comprehensive real-world data infrastructure capable of tracking long-term patient outcomes. Legal frameworks are not yet fully adapted to support risk-sharing agreements, and administrative complexity deters both payers and manufacturers from experimenting with novel pricing schemes.
Despite these hurdles, Hungary has the potential to become a regional leader in outcome-based contracting if it invests in digital health infrastructure and aligns regulatory processes with EU-level initiatives like the European Health Data Space. Pilot programs, especially in oncology and rare diseases, could pave the way for broader integration across the system.
M&A activity in the pharmaceutical sector continues to accelerate globally, driven by the need to access innovation, consolidate pipelines, and expand geographic reach. Hungary is increasingly part of this trend, as international players seek entry into the CEE market.
Recent transactions, such as the acquisition of BioCo Kft. by Belgium-based Ceres Pharma NV, highlight how Hungarian companies are becoming attractive targets for foreign investors. These deals reflect a broader strategic realignment, where domestic firms must either scale up or partner internationally to remain competitive.
At the same time, Hungary’s skilled workforce in the pharmaceutical industry, favorable R&D incentives, and established manufacturing base make it a compelling destination for inbound investment. To fully capitalize on these trends, Hungarian firms must enhance their innovation capabilities and improve integration readiness.
Trade relations between the European Union (EU) and the United States of America (US) have grown increasingly complex, with pharmaceutical products potentially affected by broader tariff disputes. While medicines have traditionally been exempted from tariffs, recent tensions over intellectual property, and regulatory standards have raised concerns about future disruptions.
Hungary, which relies on both EU and US markets for the import and export of active pharmaceutical ingredients (APIs), medical devices, and finished medicinal products, is particularly vulnerable. Any increase in tariffs or regulatory divergence could lead to higher costs, supply chain delays, and reduced competitiveness.
Moreover, Hungarian manufacturers that are part of global supply chains may face indirect exposure to trade tensions, especially if parent companies or key partners are impacted. To mitigate these risks, firms must consider diversifying sourcing strategies, investing in local production capabilities, and closely monitoring geopolitical developments.
To navigate these global shifts, Hungary’s pharmaceutical sector must adopt a forward-looking strategy built on resilience, innovation, and collaboration:
1. Strengthen data infrastructure: Building interoperable health data systems is essential for enabling outcome-based payment models and supporting evidence-based decision-making.
2. Encourage innovation and R&D: Hungary’s strong academic base and R&D incentives should be leveraged to foster innovation, particularly in biotech and personalized medicine.
3. Enhance regulatory flexibility: Updating legal frameworks to support flexible pricing and reimbursement models will be key to adapting to new payment paradigms.
4. Promote strategic partnerships: Collaboration between domestic firms and international players can unlock new growth opportunities and improve market access.
5. Monitor and adapt to trade risks: Staying ahead of trade policy developments and diversifying supply chains will help ensure resilience in an increasingly volatile global environment.
Hungary’s pharmaceutical sector is being reshaped by global forces that demand strategic agility and proactive adaptation. The rise of outcome-based payment models challenges traditional reimbursement systems, while M&A activity, such as the BioCo acquisition, highlights the growing importance of scale and international integration. Meanwhile, trade tensions between the EU and US add a layer of uncertainty that cannot be ignored.
By investing in innovation, data infrastructure, and strategic partnerships, Hungary can not only weather these changes but emerge stronger and more competitive in the global pharmaceutical arena.
This article was first published in the Pharma Industry Review 2025 / 2. print issue.
Producing journalism that is worthy of the name is a costly business. For over 30 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
